TNFRSF17 and neoplasm: The total incidence is close to 90%, yet severe, grade ≥3 CRS is reported less than 10% for most anti-BCMA products [14,15,20,21,33,40]; however, there are some exceptions, including the BCMA-targeted CAR T-cell constructs from UPENN and NCI with grade ≥3 of 32% and 38% respectively, due to host characteristics, high tumor burden, different co-stimulatory domain, and CAR T-cell dose [20,21].